EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Multizentrische StudieOpen Access · CC BY 4.0

Baseline tumor burden and outcomes in patients with rare cancers treated with immunotherapy (Southwest Oncology Group trial S1609)

Paul L Swiecicki iD, Megan Othus, Sandip P Patel, Young Kwang-Chae, Razelle Kurzrock

Cancer · 01.04.2026 · 132 (7)

DOI: 10.1002/cncr.70374 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Cancer, online erschienen am 27.03.2026. Verfasst von Paul L Swiecicki und 4 weiteren Autor:innen. Beteiligte Einrichtung: University of Michigan Rogel Cancer Center, Ann Arbor, Michigan, USA. Hauptthemen laut MEDLINE: Tumor Burden, Neoplasms, Antineoplastic Combined Chemotherapy Protocols, Immunotherapy. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

It has been suggested that baseline tumor burden may correlate with immune checkpoint inhibitor (ICI) outcome for individual tumor types in which ICIs are standardly used. The authors investigated whether pretreatment tumor burden correlates with overall survival (OS), progression‐free survival (PFS), and tumor regression among patients who had rare cancers treated with dual ICIs.

Methods

Southwest Oncology Group study S1609 was a phase 2, National Cancer Institute/Southwest Oncology Group basket study (>1000 sites) evaluating nivolumab plus ipilimumab in 53 cohorts of patients who had rare/ultrarare malignancies (ClinicalTrials.gov identifier NCT02834013). Overall, 722 patients were included in this secondary analysis, all of whom had measurable disease (Response Evaluation Criteria in Solid Tumors, version 1.1). Baseline tumor burden, defined as the sum of the greatest dimensions of target lesions at study registration, was analyzed based on quartiles observed in the data. The number of target lesions was also considered a secondary tumor burden measure. End points included OS and PFS.

Results

Larger baseline tumor burden correlated with shorter OS, but not PFS (multivariable analysis). Higher baseline tumor burden quartiles had only a weak negative association with any tumor regression at first scan (Fisher exact test, p = .09), and multivariable analyses further indicated that both tumor burden and any tumor regression at first posttreatment scan were independently associated with OS in multivariable analysis (comparing a baseline tumor size ≥12.9 cm vs. 1.0–4.8 cm; hazard ratio, 1.64; 95% confidence interval, 1.02–1.72; p = .032), but there was no evidence of an interaction between tumor burden and any tumor regression at the first scan ( p for interaction > .65).

Conclusions

Larger baseline tumor burden was associated with worse OS, but not PFS, and was not predictive of tumor regression after dual ICI therapy in a large cohort with rare cancer types.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Tumor BurdenNeoplasmsAntineoplastic Combined Chemotherapy ProtocolsImmunotherapyRare DiseasesImmune Checkpoint InhibitorsHumansFemaleMaleMiddle AgedAgedIpilimumabNivolumabAdultTreatment OutcomeProgression-Free SurvivalAged, 80 and over

Stichwörter der Autor:innen

Response Evaluation Criteria in Solid Tumors (RECIST)Southwest Oncology Group study S1609immune checkpoint inhibitorimmunotherapypredictive biomarkersrare cancerstumor burden

Substanzen

IpilimumabNivolumabImmune Checkpoint Inhibitors

Autor:innen und Institutionen

  • University of Michigan Rogel Cancer Center, Ann Arbor, Michigan, USA.
  • Southwest Oncology Group Cancer Research Network Statistical Center, Seattle, Washington, USA.
  • Fred Hutchinson Cancer Center, Seattle, Washington, USA.
  • University of California at San Diego Moores Cancer Center, La Jolla, California, USA.
  • Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA.
  • Medical College of Wisconsin, Milwaukee, Wisconsin, USA.

ORCID-Profile: Paul L Swiecicki

Förderung

  • NCI NIH HHS

Zitieren

APA

Swiecicki, P. L., Othus, M., Patel, S. P., Kwang-Chae, Y., & Kurzrock, R. (2026). Baseline tumor burden and outcomes in patients with rare cancers treated with immunotherapy (Southwest Oncology Group trial S1609). Cancer, 132(7). https://doi.org/10.1002/cncr.70374

Vancouver

Swiecicki PL, Othus M, Patel SP, Kwang-Chae Y, Kurzrock R. Baseline tumor burden and outcomes in patients with rare cancers treated with immunotherapy (Southwest Oncology Group trial S1609). Cancer. 2026;132(7). doi:10.1002/cncr.70374

BibTeX
@article{Swiecicki2026,
  author = {Swiecicki, Paul L and Othus, Megan and Patel, Sandip P and Kwang-Chae, Young and Kurzrock, Razelle},
  title = {Baseline tumor burden and outcomes in patients with rare cancers treated with immunotherapy (Southwest Oncology Group trial S1609)},
  journal = {Cancer},
  year = {2026},
  volume = {132},
  number = {7},
  doi = {10.1002/cncr.70374}
}
Kostenlos starten →